Published by Coherent Market Insights
Posted on September 20, 2021
Coherent Market Insights released a new market study on 2021-2027 Cancer Metabolism Based Therapeutics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The research study provides estimates for 2021-2027 Cancer Metabolism Based Therapeutics Market Forecast till 2027*.
Request Here For Market Latest Insights: https://www.coherentmarketinsights.com/insight/request-pdf/961
The advent of advanced therapies and the increasing prevalence of cancer around the globe is facilitating the growth of the global cancer metabolism-based therapeutics market. According to the International Agency for Research on Cancer, cancer is among the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. Targeting cancer metabolism conditions is projected to serve major growth opportunities for rare drugs to treat multiple types of cancer. Changing lifestyle and growing aging population is also contributing to the risk of developing cancer among the population.
Cancer metabolism therapy is based on the idea that tumors have a different metabolic process from normal or healthy cells. While normal cells secrete glycogen and glucose, cancer cells exhibit a lack of glycogen and glucose as well as increased levels of lactic acid. Cancer patients also have a decreased ability to use oxygen as well as an increased use of fatty acids as fuel. This metabolite imbalance is what underlies most of the complications associated with cancer. Cancer therapies that use various types of biological therapies are used to directly target this metabolic disorder.
Regional assessment reveals that, North America is estimated to gain significant growth in the near future and this is attributed to the increasing FDA approval for commercializing cancer metabolism-based therapeutics. For example, in September 2017, the FDA approved Agios’ and Celgene’s enasidenib for acute myeloid leukemia (AML), validating metabolism-modulating drugs as a means of killing cancer cells. Enasidenib (formerly AG-221) is a first-in-class inhibitor of mutated isocitrate dehydro genase 2 (IDH2). Another instance, in August 2020, Tyme Technologies, Inc. a biotechnology company developing cancer metabolism-based therapies (CMBTs
) announced that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its lead pipeline candidate, SM-88 (racemetyrosine), as a treatment for patients with pancreatic cancer.
Key Developments:
In January 2021, Elypta has granted a US patent for its liquid biopsy method as a cancer metabolism therapy
In January 2019, Drugmaker Lupin announced that it is in the process of developing a pipeline of products under its new drug discovery program to treat various diseases like cancer and metabolic disorders
In December 2020, Rafael Pharmaceuticals Inc. provider of cancer metabolism-based therapeutics announced it has initiated a Phase 2 clinical trial of CPI-613® (devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue
Cancer Metabolism Based Therapeutics Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/961
Reasons to Purchase this Report
• Current and future of global Cancer Metabolism Based Therapeutics Market outlook in the developed and emerging markets • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period. • Regions/countries that are expected to witness the fastest growth rates during the forecast period • The latest developments, market shares, and strategies that are employed by the major market players
Major Point Answered in Cancer Metabolism Based Therapeutics Market Research Study are:
Request Here Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/961
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Cancer Metabolism Based Therapeutics Market Major Vendors Are Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical appeared first on Gatorledger.
Coherent Market Insights released a new market study on 2021-2027 Cancer Metabolism Based Therapeutics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The research study provides estimates for 2021-2027 Cancer Metabolism Based Therapeutics Market Forecast till 2027*.
Request Here For Market Latest Insights: https://www.coherentmarketinsights.com/insight/request-pdf/961
The advent of advanced therapies and the increasing prevalence of cancer around the globe is facilitating the growth of the global cancer metabolism-based therapeutics market. According to the International Agency for Research on Cancer, cancer is among the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. Targeting cancer metabolism conditions is projected to serve major growth opportunities for rare drugs to treat multiple types of cancer. Changing lifestyle and growing aging population is also contributing to the risk of developing cancer among the population.
Cancer metabolism therapy is based on the idea that tumors have a different metabolic process from normal or healthy cells. While normal cells secrete glycogen and glucose, cancer cells exhibit a lack of glycogen and glucose as well as increased levels of lactic acid. Cancer patients also have a decreased ability to use oxygen as well as an increased use of fatty acids as fuel. This metabolite imbalance is what underlies most of the complications associated with cancer. Cancer therapies that use various types of biological therapies are used to directly target this metabolic disorder.
Regional assessment reveals that, North America is estimated to gain significant growth in the near future and this is attributed to the increasing FDA approval for commercializing cancer metabolism-based therapeutics. For example, in September 2017, the FDA approved Agios’ and Celgene’s enasidenib for acute myeloid leukemia (AML), validating metabolism-modulating drugs as a means of killing cancer cells. Enasidenib (formerly AG-221) is a first-in-class inhibitor of mutated isocitrate dehydro genase 2 (IDH2). Another instance, in August 2020, Tyme Technologies, Inc. a biotechnology company developing cancer metabolism-based therapies (CMBTs) announced that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its lead pipeline candidate, SM-88 (racemetyrosine), as a treatment for patients with pancreatic cancer.
Key Developments:
In January 2021, Elypta has granted a US patent for its liquid biopsy method as a cancer metabolism therapy
In January 2019, Drugmaker Lupin announced that it is in the process of developing a pipeline of products under its new drug discovery program to treat various diseases like cancer and metabolic disorders
In December 2020, Rafael Pharmaceuticals Inc. provider of cancer metabolism-based therapeutics announced it has initiated a Phase 2 clinical trial of CPI-613® (devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue
Cancer Metabolism Based Therapeutics Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/961
Reasons to Purchase this Report
• Current and future of global Cancer Metabolism Based Therapeutics Market outlook in the developed and emerging markets • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period. • Regions/countries that are expected to witness the fastest growth rates during the forecast period • The latest developments, market shares, and strategies that are employed by the major market players
Major Point Answered in Cancer Metabolism Based Therapeutics Market Research Study are:
Request Here Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/961
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Cancer Metabolism Based Therapeutics Market Major Vendors Are Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical appeared first on Gatorledger.
Explore more articles in the Research Reports category
